Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments

Michael R. Eber, Dana P. Goldman, Darius N. Lakdawalla, Tomas J. Philipson, Daryl Pritchard, Marco Huesch, Nicholas Summers, Mark T. Linthicum, Jeff Sullivan, Robert W. Dubois

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim: This study aims to analyze the impacts of a range of clinical evidence generation scenarios associated with comparative effectiveness research (CER) on pharmaceutical innovation. Materials & methods: We used the Global Pharmaceutical Policy Model to project the effect of changes in pharmaceutical producer costs, revenues and timings on drug innovation and health for the age 55+ populations in the USA and Europe through year 2060 using three clinical scenarios. Results: Changes in producer incentives from widespread CER evidence generation and use had varied but often large predicted impacts on simulated outcomes in 2060. Effect on the number of new drug introductions ranged from a 81.1% reduction to a 45.5% increase, and the effect on population-level life expectancy ranged from a 15.6% reduction to a 11.4% increase compared to baseline estimates. Conclusion: The uncertainty surrounding the consequences of increased clinical evidence generation and use on innovation calls for a carefully measured approach to CER implementation, balancing near-term benefits to spending and health with long-term implications for innovation.

Original languageEnglish (US)
Pages (from-to)203-213
Number of pages11
JournalJournal of Comparative Effectiveness Research
Volume4
Issue number3
DOIs
StatePublished - May 1 2015

Fingerprint

Comparative Effectiveness Research
Pharmaceutical Preparations
Drug and Narcotic Control
Health
Life Expectancy
Population
Uncertainty
Motivation
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

Eber, M. R., Goldman, D. P., Lakdawalla, D. N., Philipson, T. J., Pritchard, D., Huesch, M., ... Dubois, R. W. (2015). Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments. Journal of Comparative Effectiveness Research, 4(3), 203-213. https://doi.org/10.2217/cer.15.9
Eber, Michael R. ; Goldman, Dana P. ; Lakdawalla, Darius N. ; Philipson, Tomas J. ; Pritchard, Daryl ; Huesch, Marco ; Summers, Nicholas ; Linthicum, Mark T. ; Sullivan, Jeff ; Dubois, Robert W. / Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments. In: Journal of Comparative Effectiveness Research. 2015 ; Vol. 4, No. 3. pp. 203-213.
@article{534c38e23e42471a8710a28c90f54c85,
title = "Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments",
abstract = "Aim: This study aims to analyze the impacts of a range of clinical evidence generation scenarios associated with comparative effectiveness research (CER) on pharmaceutical innovation. Materials & methods: We used the Global Pharmaceutical Policy Model to project the effect of changes in pharmaceutical producer costs, revenues and timings on drug innovation and health for the age 55+ populations in the USA and Europe through year 2060 using three clinical scenarios. Results: Changes in producer incentives from widespread CER evidence generation and use had varied but often large predicted impacts on simulated outcomes in 2060. Effect on the number of new drug introductions ranged from a 81.1{\%} reduction to a 45.5{\%} increase, and the effect on population-level life expectancy ranged from a 15.6{\%} reduction to a 11.4{\%} increase compared to baseline estimates. Conclusion: The uncertainty surrounding the consequences of increased clinical evidence generation and use on innovation calls for a carefully measured approach to CER implementation, balancing near-term benefits to spending and health with long-term implications for innovation.",
author = "Eber, {Michael R.} and Goldman, {Dana P.} and Lakdawalla, {Darius N.} and Philipson, {Tomas J.} and Daryl Pritchard and Marco Huesch and Nicholas Summers and Linthicum, {Mark T.} and Jeff Sullivan and Dubois, {Robert W.}",
year = "2015",
month = "5",
day = "1",
doi = "10.2217/cer.15.9",
language = "English (US)",
volume = "4",
pages = "203--213",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6305",
publisher = "Future Medicine Ltd.",
number = "3",

}

Eber, MR, Goldman, DP, Lakdawalla, DN, Philipson, TJ, Pritchard, D, Huesch, M, Summers, N, Linthicum, MT, Sullivan, J & Dubois, RW 2015, 'Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments', Journal of Comparative Effectiveness Research, vol. 4, no. 3, pp. 203-213. https://doi.org/10.2217/cer.15.9

Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments. / Eber, Michael R.; Goldman, Dana P.; Lakdawalla, Darius N.; Philipson, Tomas J.; Pritchard, Daryl; Huesch, Marco; Summers, Nicholas; Linthicum, Mark T.; Sullivan, Jeff; Dubois, Robert W.

In: Journal of Comparative Effectiveness Research, Vol. 4, No. 3, 01.05.2015, p. 203-213.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments

AU - Eber, Michael R.

AU - Goldman, Dana P.

AU - Lakdawalla, Darius N.

AU - Philipson, Tomas J.

AU - Pritchard, Daryl

AU - Huesch, Marco

AU - Summers, Nicholas

AU - Linthicum, Mark T.

AU - Sullivan, Jeff

AU - Dubois, Robert W.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Aim: This study aims to analyze the impacts of a range of clinical evidence generation scenarios associated with comparative effectiveness research (CER) on pharmaceutical innovation. Materials & methods: We used the Global Pharmaceutical Policy Model to project the effect of changes in pharmaceutical producer costs, revenues and timings on drug innovation and health for the age 55+ populations in the USA and Europe through year 2060 using three clinical scenarios. Results: Changes in producer incentives from widespread CER evidence generation and use had varied but often large predicted impacts on simulated outcomes in 2060. Effect on the number of new drug introductions ranged from a 81.1% reduction to a 45.5% increase, and the effect on population-level life expectancy ranged from a 15.6% reduction to a 11.4% increase compared to baseline estimates. Conclusion: The uncertainty surrounding the consequences of increased clinical evidence generation and use on innovation calls for a carefully measured approach to CER implementation, balancing near-term benefits to spending and health with long-term implications for innovation.

AB - Aim: This study aims to analyze the impacts of a range of clinical evidence generation scenarios associated with comparative effectiveness research (CER) on pharmaceutical innovation. Materials & methods: We used the Global Pharmaceutical Policy Model to project the effect of changes in pharmaceutical producer costs, revenues and timings on drug innovation and health for the age 55+ populations in the USA and Europe through year 2060 using three clinical scenarios. Results: Changes in producer incentives from widespread CER evidence generation and use had varied but often large predicted impacts on simulated outcomes in 2060. Effect on the number of new drug introductions ranged from a 81.1% reduction to a 45.5% increase, and the effect on population-level life expectancy ranged from a 15.6% reduction to a 11.4% increase compared to baseline estimates. Conclusion: The uncertainty surrounding the consequences of increased clinical evidence generation and use on innovation calls for a carefully measured approach to CER implementation, balancing near-term benefits to spending and health with long-term implications for innovation.

UR - http://www.scopus.com/inward/record.url?scp=84930510987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930510987&partnerID=8YFLogxK

U2 - 10.2217/cer.15.9

DO - 10.2217/cer.15.9

M3 - Article

AN - SCOPUS:84930510987

VL - 4

SP - 203

EP - 213

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

SN - 2042-6305

IS - 3

ER -